PL3142751T3 - Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca - Google Patents

Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca

Info

Publication number: PL3142751T3
Authority: PL; Poland
Prior art keywords: ctla; antibodies; lung cancer; small cell; cell lung
Prior art date: 2014-05-13

Application number

PL15722195T

Other languages

English (en)

Inventor

Rajesh Narwal

Paul Robbins

Joyson KARAKUNNEL

Mohammed M. Dar

Original Assignee

Medimmune Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-13

Filing date

2015-05-12

Publication date

2019-12-31

2015-05-12 Application filed by Medimmune Limited filed Critical Medimmune Limited

2019-12-31 Publication of PL3142751T3 publication Critical patent/PL3142751T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL15722195T 2014-05-13 2015-05-12 Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca PL3142751T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201461992658P	2014-05-13	2014-05-13
US201562105992P	2015-01-21	2015-01-21
US201562114336P	2015-02-10	2015-02-10
PCT/EP2015/060523 WO2015173267A1 (en)	2014-05-13	2015-05-12	Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
EP15722195.3A EP3142751B1 (en)	2014-05-13	2015-05-12	Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Publications (1)

Publication Number	Publication Date
PL3142751T3 true PL3142751T3 (pl)	2019-12-31

Family

ID=53175516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15722195T PL3142751T3 (pl)	2014-05-13	2015-05-12	Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca

Country Status (27)

Country	Link
US (3)	US10232040B2 (pl)
EP (2)	EP3142751B1 (pl)
JP (4)	JP6648038B2 (pl)
KR (4)	KR20220162844A (pl)
CN (2)	CN113230398B (pl)
AU (4)	AU2015260962B2 (pl)
BR (1)	BR122023025321A2 (pl)
CA (1)	CA2947471A1 (pl)
CY (1)	CY1122642T1 (pl)
DK (1)	DK3142751T3 (pl)
ES (1)	ES2749098T3 (pl)
GB (1)	GB2531094A (pl)
HR (1)	HRP20191449T1 (pl)
HU (1)	HUE045965T2 (pl)
IL (2)	IL248528B (pl)
LT (1)	LT3142751T (pl)
ME (1)	ME03493B (pl)
MX (1)	MX373019B (pl)
PL (1)	PL3142751T3 (pl)
PT (1)	PT3142751T (pl)
RS (1)	RS59134B1 (pl)
RU (1)	RU2702332C2 (pl)
SG (2)	SG10201810108PA (pl)
SI (1)	SI3142751T1 (pl)
SM (1)	SMT201900544T1 (pl)
TW (3)	TW202123967A (pl)
WO (1)	WO2015173267A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20210143932A (ko) *	2013-09-11	2021-11-29	메디뮨 리미티드	종양 치료용 항-ｂ7-ｈ1 항체
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
SMT201900544T1 (it) *	2014-05-13	2019-11-13	Medimmune Ltd	Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
GB2535256A (en) *	2014-08-28	2016-08-17	Medimmune Ltd	Combination therapy for PD-L1 negative tumors
WO2016030455A1 (en) *	2014-08-28	2016-03-03	Medimmune Limited	Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
WO2016149201A2 (en)	2015-03-13	2016-09-22	Cytomx Therapeutics, Inc.	Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3448428A4 (en) *	2016-04-25	2019-11-27	Medimmune, LLC	COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
EP3458612B1 (en)	2016-05-17	2023-11-15	Genecentric Therapeutics, Inc.	Methods for subtyping of lung adenocarcinoma
WO2017201164A1 (en)	2016-05-17	2017-11-23	Genecentric Diagnostics, Inc.	Methods for subtyping of lung squamous cell carcinoma
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018029474A2 (en)	2016-08-09	2018-02-15	Kymab Limited	Anti-icos antibodies
JP7198752B2 (ja)	2016-08-09	2023-01-04	カイマブ・リミテッド	抗ｉｃｏｓ抗体
KR20230011473A (ko)	2016-09-06	2023-01-20	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089780A1 (en) *	2016-11-11	2018-05-17	Medimmune, Llc	Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
US11040027B2 (en)	2017-01-17	2021-06-22	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
IL320916A (en) *	2017-02-16	2025-07-01	Medimmune Llc	Bladder cancer treatment with anti-PD-L1 antibody
CN110914302A (zh)	2017-06-01	2020-03-24	赛托姆克斯治疗学股份有限公司	可活化抗pdl1抗体及其使用方法
GB201709808D0 (en)	2017-06-20	2017-08-02	Kymab Ltd	Antibodies
US11629189B2 (en)	2017-12-19	2023-04-18	Kymab Limited	Bispecific antibody for ICOS and PD-L1
GB201721338D0 (en)	2017-12-19	2018-01-31	Kymab Ltd	Anti-icos Antibodies
AU2018412532B2 (en) *	2018-03-08	2025-05-08	Astrazeneca Ab	Compositions and methods for treating late stage lung cancer
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7487558B2 (ja)	2020-05-25	2024-05-21	船井電機株式会社	面光源装置および表示装置
KR20230035576A (ko)	2020-07-07	2023-03-14	비온테크 에스이	Hpv 양성 암 치료용 rna
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
TW202304506A (zh)	2021-03-25	2023-02-01	日商安斯泰來製藥公司	涉及抗claudin 18.2抗體的組合治療以治療癌症
WO2022243378A1 (en)	2021-05-18	2022-11-24	Kymab Limited	Uses of anti-icos antibodies
GB202107994D0 (en)	2021-06-04	2021-07-21	Kymab Ltd	Treatment of cancer
AU2022312698A1 (en)	2021-07-13	2024-01-25	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023051926A1 (en)	2021-09-30	2023-04-06	BioNTech SE	Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
MX2024004429A (es) *	2021-10-29	2024-05-06	Oncoc4 Inc	Regimenes de dosificacion del anticuerpo anti-ctla-4.
WO2023083439A1 (en)	2021-11-09	2023-05-19	BioNTech SE	Tlr7 agonist and combinations for cancer treatment
US20250340641A1 (en)	2022-05-18	2025-11-06	Kymab Limited	Uses of anti-icos antibodies
AU2023401158A1 (en)	2022-12-01	2025-05-29	BioNTech SE	Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN120418289A (zh)	2022-12-14	2025-08-01	安斯泰来制药欧洲有限公司	结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
CN120813375A (zh)	2023-01-30	2025-10-17	凯玛布有限公司	抗体
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025121445A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7109003B2 (en)	1998-12-23	2006-09-19	Abgenix, Inc.	Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
US7158164B2 (en)	2003-08-29	2007-01-02	Fuji Photo Film Co., Ltd.	Thermal development method and apparatus
AU2011203119C1 (en)	2005-05-09	2018-06-14	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) *	2005-07-01	2016-04-05	이. 알. 스퀴부 앤드 선즈, 엘.엘.씨.	예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2007423A2 (en) *	2006-04-05	2008-12-31	Pfizer Products Incorporated	Ctla4 antibody combination therapy
US20100055111A1 (en) *	2007-02-14	2010-03-04	Med. College Of Georgia Research Institute, Inc.	Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
CN104961829B (zh)	2009-11-24	2018-08-21	米迪缪尼有限公司	针对b7-h1的靶向结合剂
CN102000947B (zh) *	2010-10-14	2012-06-06	沈阳飞机工业（集团）有限公司	两半轴瓦的铣切加工方法
HUE044038T2 (hu)	2010-11-05	2019-09-30	Novartis Ag	Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
CN101975831B (zh) *	2010-11-25	2012-09-05	中国检验检疫科学研究院	高效液相色谱法测定化妆品中苯酚磺酸锌的方法
US8609625B2 (en) *	2011-06-24	2013-12-17	Taipei Veterans General Hospital	Method for enhancing immune response in the treatment of infectious and malignant diseases
US9863935B2 (en) *	2012-05-08	2018-01-09	H. Lee Moffitt Cancer And Research Institute, Inc.	Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
WO2013172926A1 (en) *	2012-05-14	2013-11-21	Yale University	Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
KR102702287B1 (ko) *	2012-05-15	2024-09-04	브리스톨-마이어스 스큅 컴퍼니	Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
WO2014066834A1 (en)	2012-10-26	2014-05-01	The University Of Chicago	Synergistic combination of immunologic inhibitors for the treatment of cancer
US9107960B2 (en) *	2012-12-13	2015-08-18	Immunimedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
EP3563836A1 (en) *	2013-03-01	2019-11-06	Astex Pharmaceuticals, Inc.	Drug combinations
SMT201900544T1 (it) *	2014-05-13	2019-11-13	Medimmune Ltd	Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
WO2016030455A1 (en) *	2014-08-28	2016-03-03	Medimmune Limited	Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
CN112778418B (zh) *	2014-11-10	2025-04-22	免疫医疗有限公司	对cd73具有特异性的结合分子及其用途
KR20250004095A (ko) *	2015-04-17	2025-01-07	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
US20160347848A1 (en) *	2015-05-28	2016-12-01	Medimmune Limited	Therapeutic combinations and methods for treating neoplasia
EP3448428A4 (en) *	2016-04-25	2019-11-27	Medimmune, LLC	COMPOSITIONS WITH CO FORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
IL320916A (en) *	2017-02-16	2025-07-01	Medimmune Llc	Bladder cancer treatment with anti-PD-L1 antibody
US12042527B2 (en) *	2019-01-08	2024-07-23	Modernatx, Inc.	Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers

2015
- 2015-05-12 SM SM20190544T patent/SMT201900544T1/it unknown
- 2015-05-12 SG SG10201810108PA patent/SG10201810108PA/en unknown
- 2015-05-12 KR KR1020227040764A patent/KR20220162844A/ko not_active Ceased
- 2015-05-12 HR HRP20191449 patent/HRP20191449T1/hr unknown
- 2015-05-12 ME MEP-2019-231A patent/ME03493B/me unknown
- 2015-05-12 DK DK15722195.3T patent/DK3142751T3/da active
- 2015-05-12 US US14/710,101 patent/US10232040B2/en active Active
- 2015-05-12 LT LTEP15722195.3T patent/LT3142751T/lt unknown
- 2015-05-12 GB GB1508097.1A patent/GB2531094A/en not_active Withdrawn
- 2015-05-12 RS RS20191070A patent/RS59134B1/sr unknown
- 2015-05-12 BR BR122023025321-3A patent/BR122023025321A2/pt not_active Application Discontinuation
- 2015-05-12 PL PL15722195T patent/PL3142751T3/pl unknown
- 2015-05-12 SG SG11201609285SA patent/SG11201609285SA/en unknown
- 2015-05-12 KR KR1020167031692A patent/KR102333658B1/ko active Active
- 2015-05-12 CN CN202110380316.8A patent/CN113230398B/zh active Active
- 2015-05-12 KR KR1020237040802A patent/KR20230165876A/ko not_active Ceased
- 2015-05-12 KR KR1020217038830A patent/KR20210149870A/ko not_active Ceased
- 2015-05-12 EP EP15722195.3A patent/EP3142751B1/en active Active
- 2015-05-12 CA CA2947471A patent/CA2947471A1/en active Pending
- 2015-05-12 JP JP2016567088A patent/JP6648038B2/ja active Active
- 2015-05-12 MX MX2016014189A patent/MX373019B/es active IP Right Grant
- 2015-05-12 PT PT157221953T patent/PT3142751T/pt unknown
- 2015-05-12 RU RU2016148645A patent/RU2702332C2/ru active
- 2015-05-12 HU HUE15722195A patent/HUE045965T2/hu unknown
- 2015-05-12 SI SI201530857T patent/SI3142751T1/sl unknown
- 2015-05-12 EP EP19190351.7A patent/EP3603748A1/en active Pending
- 2015-05-12 AU AU2015260962A patent/AU2015260962B2/en active Active
- 2015-05-12 CN CN201580024117.6A patent/CN106456756B/zh active Active
- 2015-05-12 ES ES15722195T patent/ES2749098T3/es active Active
- 2015-05-12 WO PCT/EP2015/060523 patent/WO2015173267A1/en not_active Ceased
- 2015-05-13 TW TW109134952A patent/TW202123967A/zh unknown
- 2015-05-13 TW TW104115327A patent/TWI707692B/zh active
- 2015-05-13 TW TW110144264A patent/TWI780994B/zh active
2016
- 2016-10-26 IL IL248528A patent/IL248528B/en active IP Right Grant
2019
- 2019-01-24 US US16/256,022 patent/US11446377B2/en active Active
- 2019-10-03 CY CY20191101034T patent/CY1122642T1/el unknown
2020
- 2020-01-15 JP JP2020004032A patent/JP2020090509A/ja active Pending
- 2020-08-04 IL IL276481A patent/IL276481B/en unknown
- 2020-09-10 AU AU2020230309A patent/AU2020230309B2/en active Active
2021
- 2021-03-10 JP JP2021037883A patent/JP2021098734A/ja active Pending
2022
- 2022-08-09 US US17/818,546 patent/US20230115328A1/en active Pending
2023
- 2023-01-25 JP JP2023009115A patent/JP7519477B2/ja active Active
- 2023-07-04 AU AU2023204286A patent/AU2023204286B2/en active Active
2025
- 2025-04-24 AU AU2025202908A patent/AU2025202908A1/en active Pending

Also Published As

Publication number	Publication date
IL276481B (en)	2022-06-01
TWI780994B (zh)	2022-10-11
DK3142751T3 (da)	2019-10-14
MX373019B (es)	2020-03-31
AU2023204286A1 (en)	2023-07-27
US20230115328A1 (en)	2023-04-13
HRP20191449T1 (hr)	2019-11-15
EP3603748A1 (en)	2020-02-05
SG11201609285SA (en)	2016-12-29
WO2015173267A1 (en)	2015-11-19
RU2019129614A3 (pl)	2021-12-27
BR112016026197A2 (pt)	2018-02-20
CN113230398B (zh)	2025-01-03
JP2017520520A (ja)	2017-07-27
SMT201900544T1 (it)	2019-11-13
JP2023052607A (ja)	2023-04-11
AU2023204286B2 (en)	2025-02-06
ME03493B (me)	2020-01-20
US20150328311A1 (en)	2015-11-19
GB201508097D0 (en)	2015-06-24
IL248528A0 (en)	2016-12-29
IL276481A (en)	2020-09-30
TW201545759A (zh)	2015-12-16
AU2020230309B2 (en)	2023-04-20
CN106456756A (zh)	2017-02-22
US20190240324A1 (en)	2019-08-08
KR20170003575A (ko)	2017-01-09
AU2015260962A1 (en)	2016-11-24
SI3142751T1 (sl)	2019-09-30
KR20210149870A (ko)	2021-12-09
JP2020090509A (ja)	2020-06-11
TW202123967A (zh)	2021-07-01
LT3142751T (lt)	2019-09-25
EP3142751A1 (en)	2017-03-22
TW202233239A (zh)	2022-09-01
US11446377B2 (en)	2022-09-20
IL248528B (en)	2020-08-31
AU2025202908A1 (en)	2025-05-15
BR122023025321A2 (pt)	2024-02-20
JP7519477B2 (ja)	2024-07-19
MX2016014189A (es)	2017-05-04
CN106456756B (zh)	2021-04-23
ES2749098T3 (es)	2020-03-19
KR20220162844A (ko)	2022-12-08
RS59134B1 (sr)	2019-09-30
CY1122642T1 (el)	2021-03-12
HUE045965T2 (hu)	2020-01-28
AU2015260962B2 (en)	2020-06-11
PT3142751T (pt)	2019-10-25
JP6648038B2 (ja)	2020-02-14
RU2019129614A (ru)	2020-07-16
TWI707692B (zh)	2020-10-21
US10232040B2 (en)	2019-03-19
CN113230398A (zh)	2021-08-10
KR102333658B1 (ko)	2021-12-01
KR20230165876A (ko)	2023-12-05
RU2702332C2 (ru)	2019-10-08
CA2947471A1 (en)	2015-11-19
EP3142751B1 (en)	2019-08-07
GB2531094A (en)	2016-04-13
RU2016148645A3 (pl)	2018-12-21
SG10201810108PA (en)	2018-12-28
AU2020230309A1 (en)	2020-10-01
RU2016148645A (ru)	2018-06-19
JP2021098734A (ja)	2021-07-01

Publication	Publication Date	Title
IL276481B (en)	2022-06-01	Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer
IL267803A (en)	2019-09-26	Methods for treating cancer with anti-tim-3 antibodies
IL252610A0 (en)	2017-07-31	Methods and preparations for the treatment of cancer
IL253462B2 (en)	2023-03-01	Cancer treatment with monoclonal antibodies against a latency-related peptide
PT3063173T (pt)	2020-10-20	Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
EP3177292A4 (en)	2018-04-11	Compounds and methods for treating cancer
IL252716A0 (en)	2017-08-31	Anti-csf1r antibodies for the treatment of pvns
TWI560201B (en)	2016-12-01	Bi-specific antibodies for treating cancer
EP3191128A4 (en)	2018-03-14	Uses of anti-her3 antibodies for treating cancer
IL246607A0 (en)	2016-08-31	Improved cellular preparations and methods for cancer treatment
IL262656A (en)	2018-12-31	Nanoliposomal irinotecan for use in the treatment of small cell lung cancer
IL250507A0 (en)	2017-03-30	Anti-ck8 antibodies for use in cancer therapy
IL255079A0 (en)	2017-12-31	Methods of treating lung cancer
IL246558A0 (en)	2016-08-31	New methods of cancer treatment
EP3119426A4 (en)	2018-02-28	Methods and materials for treating cancer
EP3119427A4 (en)	2017-11-15	Methods and materials for treating cancer
EP3240566A4 (en)	2018-06-06	Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3273970A4 (en)	2018-09-12	Methods and materials for treating cancer
EP3538142A4 (en)	2020-07-01	ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
GB201411393D0 (en)	2014-08-13	Agents and methods for determining colorectal cancer status
EP3177637B8 (en)	2020-08-19	Kpv for treating colorectal cancer and ibd
GB201414904D0 (en)	2014-10-08	Materials and methods for treating cancer
HK1233707A1 (en)	2018-02-02	Reagents and methods for breast cancer detection